NAD+: The Cellular Energy Coenzyme

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It plays a central role in metabolism, acting as a shuttle that helps cells convert nutrients into usable energy. Beyond energy production, NAD+ is a substrate for enzymes involved in DNA repair and cellular signaling, which is part of why it has drawn so much interest in aging research.

A frequently cited observation is that NAD+ levels appear to decline with age across many tissues. This has led to the hypothesis that restoring NAD+ might support cellular health later in life. But a decline is a clue, not proof. It does not establish that topping NAD+ back up reverses aging or treats any condition. That distinction is what the trials below are built to address.

How NAD+ is thought to work

Because NAD+ itself is not absorbed well when taken orally, most research and supplementation strategies focus on precursors, molecules the body can convert into NAD+. The most studied are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). The idea is that supplying these building blocks helps cells maintain or restore NAD+ levels.

Mechanistically, NAD+ supports mitochondrial function and serves as fuel for enzyme families such as sirtuins and PARPs, which are involved in stress responses and DNA repair. A 2023 review in Endocrine Reviews lays out this biology in detail. It also stresses that key questions remain open: how tightly the body regulates tissue NAD+, and whether raising it actually delivers the benefits the mechanism predicts.

What the research shows

Human evidence is still developing, and the picture it paints is measured. A 2023 multicentre randomized controlled trial published in Geroscience examined NMN supplementation in 80 healthy middle-aged adults at doses up to 900mg daily. Blood NAD+ concentrations rose significantly across all NMN groups, no safety issues emerged, and the trial reported improvements in a six-minute walking test. Controlled trials of this kind are the most reliable type of human data available for NAD+ precursors, and they consistently show that precursors raise blood NAD+ and are well tolerated over the studied periods.

Beyond bioavailability, researchers are testing whether raising NAD+ changes meaningful outcomes. A clamp-based trial at Washington University studied NMN in postmenopausal women with prediabetes and measured insulin sensitivity with a hyperinsulinemic-euglycemic clamp, the field's gold-standard method, as its primary outcome. The largest effort to date is NOPARK, a Phase 3 trial that randomized 410 people with early Parkinson's disease to nicotinamide riboside or placebo over 52 weeks, with the MDS-UPDRS disease-severity score as its primary endpoint. Studies like these move the field past "does it raise NAD+" toward "does raising NAD+ help."

A 2025 review in Nature Metabolism on NAD+ precursor supplementation in human aging offers a balanced appraisal of the broader literature. It notes that while precursors reliably increase NAD+ markers, the trials do not yet demonstrate clear, consistent clinical benefits, and study designs, durations, and endpoints vary widely. The picture across the field is consistent: the underlying biology is well characterized, short-term safety signals are reassuring, and a meaningful anti-aging or disease-modifying benefit in people is exactly what the current wave of larger trials is built to settle.

What NAD+ is being studied for

Based on the published research and active trials, NAD+ precursors are being studied for healthy aging and metabolic health, for insulin sensitivity and cardiometabolic markers, and increasingly for neurological conditions such as Parkinson's disease. People drawn to NAD+ are often interested in supporting cellular energy and general vitality as they age, and much of the early human work focused on healthy adults before moving into specific clinical questions.

The pattern holds across these uses: a strong mechanistic case and an encouraging early safety record, with a defined clinical benefit still being established by the trials now in progress. Whether NAD+ makes sense for any one person is a question for a qualified clinician after a full assessment.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. NAD+ is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.